Mar 4, 2026 07:00AM
Mar 2, 2026 04:30PM
Feb 27, 2026 07:03AM
Feb 27, 2026 07:00AM
Sep 29, 2025 07:30AM
Sep 29, 2025 07:30AM
Sep 8, 2025 07:00AM Sitryx names Adam Mostafa as chief financial officer
Sep 8, 2025 07:00AM
Jun 10, 2025 08:02AM
Jun 10, 2025 08:00AM
Mar 25, 2025 06:01AM
Feb 19, 2025 07:35AM
Feb 19, 2025 07:35AM
Jan 29, 2025 02:48PM X4 Pharmaceuticals (XFOR) said approached by Cheisi about takeover - source
Jan 24, 2025 07:38AM
Jan 24, 2025 07:36AM
Jan 13, 2025 07:35AM
Jan 13, 2025 07:35AM
Aug 8, 2024 06:01AM
May 9, 2024 06:30AM
May 9, 2024 06:30AM X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
May 7, 2024 06:01AM
Apr 29, 2024 06:30AM
Apr 29, 2024 06:30AM
Mar 21, 2024 06:01AM
Dec 12, 2023 06:54AM
Nov 9, 2023 06:01AM
Oct 31, 2023 08:02AM X4 Pharmaceuticals (XFOR) Announces FDA Acceptance with Priority Review of U.S. NDA for Mavorixafor in WHIM Syndrome
Oct 31, 2023 08:00AM
Oct 18, 2023 08:02AM
Oct 18, 2023 08:00AM
Sep 5, 2023 08:01AM
Sep 5, 2023 08:00AM
Aug 10, 2023 06:05AM
Aug 8, 2023 04:07PM X4 Pharmaceuticals (XFOR) Appoints Christophe Arbet-Engels as Chief Medical Officer
Aug 8, 2023 04:05PM
May 16, 2023 04:01PM
May 16, 2023 04:01PM
May 15, 2023 09:10AM
May 15, 2023 09:08AM
May 4, 2023 06:05AM
Apr 12, 2023 08:00AM X4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)
Mar 21, 2023 06:05AM
Dec 12, 2022 08:30AM
Dec 7, 2022 08:43AM
Dec 7, 2022 08:43AM
Dec 7, 2022 06:19AM
Dec 6, 2022 06:26PM
Nov 29, 2022 04:05PM X4 Pharmaceuticals (XFOR) Pivotal Phase 3 Trial of Once-Daily, Oral Mavorixafor in WHIM Syndrome Met Its Primary Endpoint
Nov 29, 2022 04:01PM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All